Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total net revenue $ 146,917,000 $ 125,072,000 $ 284,137,000 $ 242,241,000
COST OF REVENUE 87,026,000 81,126,000 169,432,000 160,063,000
GROSS PROFIT 59,891,000 43,946,000 114,705,000 82,178,000
Operating expenses:        
General and administrative 60,308,000 57,951,000 121,857,000 124,199,000
Research and development 7,502,000 8,626,000 14,897,000 16,339,000
Sales and marketing 18,901,000 17,071,000 35,160,000 33,370,000
Restructuring charges 3,074,000 0 7,758,000 0
Total operating expenses 89,785,000 83,648,000 179,672,000 173,908,000
LOSS FROM OPERATIONS (29,894,000) (39,702,000) (64,967,000) (91,730,000)
Interest (income) expense, net (2,524,000) 926,000 (3,991,000) 2,227,000
Other (income) expense, net (730,000) 405,000 (616,000) 237,000
Loss before taxes (26,640,000) (41,033,000) (60,360,000) (94,194,000)
Income tax benefit (2,309,000) (5,730,000) (5,234,000) (9,483,000)
NET LOSS $ (24,331,000) $ (35,303,000) $ (55,126,000) $ (84,711,000)
NET LOSS PER SHARE        
Basic (in dollars per share) $ (0.19) $ (0.28) $ (0.44) $ (0.68)
Diluted (in dollars per share) $ (0.19) $ (0.28) $ (0.44) $ (0.68)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares) 125,356 124,068 125,192 123,850
Diluted (in shares) 125,356 124,068 125,192 123,850
Clinical Services        
Total net revenue $ 123,156,000 $ 105,635,000 $ 238,025,000 $ 204,426,000
COST OF REVENUE 71,746,000 67,035,000 139,038,000 132,302,000
GROSS PROFIT 51,410,000 38,600,000 98,987,000 72,124,000
Advanced Diagnostics        
Total net revenue 23,761,000 19,437,000 46,112,000 37,815,000
COST OF REVENUE 15,280,000 14,091,000 30,394,000 27,761,000
GROSS PROFIT $ 8,481,000 $ 5,346,000 $ 15,718,000 $ 10,054,000